Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GC3110A Quadrivalent Influenza Vaccine in Healthy Adults
NCT02352584Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GC Flu Quadrivalent in influenza (3 arms), sponsored by GC Biopharma. Primary endpoints: Geometric Mean Titer of HI Antibody at Day 21, Solicited Adverse Events and 2 more. Started Oct 2014; status: completed.
02
Drugs
GC Flu Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02352584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352584.